WEEKLY NEWSLETTER
Bisphosphonates for osteoporosis
Examples
| Generic Name | Brand Name |
|---|---|
| alendronate | Fosamax |
| etidronate (not approved by FDA for osteoporosis) | Didronel |
| ibandronate | Boniva |
| risedronate | Actonel |
| risedronate with calcium carbonate | Actonel with Calcium |
| zoledronic acid | Reclast |
You take most bisphosphonates by mouth—every day, once or twice a week, or even once a month. Zoledronic acid is given intravenously, usually only once each year.
Etidronate (Didronel) is not approved by the U.S. Food and Drug Administration (FDA) for osteoporosis. But it is used in Canada and Europe for this purpose.
How It Works
Bisphosphonates are antiresorptive medicines, which means they slow or stop the natural process that dissolves bone tissue, resulting in maintained bone density and strength. This may prevent the development of osteoporosis. If osteoporosis already has developed, slowing the rate of bone thinning reduces the risk of broken bones.
Bisphosphonates may be taken by men or women.
Why It Is Used
Bisphosphonates are commonly used for the prevention and treatment of osteopenia and osteoporosis.
Bisphosphonates are also used to treat other bone diseases such as Paget's disease.
Bisphosphonates should not be taken by:
- Pregnant women.
- People with severe kidney problems.
- People with severe heartburn or inflammation of the esophagus (the tube that connects the throat to the stomach).
How Well It Works
Studies show that alendronate (Fosamax) and risedronate (Actonel) lower the risk of fractures of the vertebrae by 50% and other fractures by 30% to 49% in people with osteoporosis. If you take alendronate or risedronate, you may not be as likely to break a bone.1 A study of postmenopausal women who took alendronate for 10 years reported increased bone density and effective prevention of fractures. This effect decreases if alendronate use is discontinued.2
Risedronate and alendronate may be taken in combination with hormone replacement therapy (HRT) for women with severe osteoporosis or for those who are not receiving adequate benefit from a bisphosphonate alone. Studies show that taking a bisphosphonate with hormone therapy results in increased bone mass when compared to taking either a bisphosphonate or estrogen alone.3, 4 But the Women's Health Initiative study reports that HRT led to a small increase in a woman's risk of certain serious diseases. Many experts recommend that long-term HRT only be considered for women with a significant risk for osteoporosis that outweighs the risks of taking HRT.5
In men, alendronate increases bone density in the spine and hip as well as total body bone density, and it helps prevent spinal fractures and decreases in height.6
Zoledronic acid reduces the risk of bone fracture in postmenopausal women. In one study, women had 70% less chance of fracturing a vertebra in their back and about 40% less chance of fracturing their hip.7
Bisphosphonates should not be taken at the same time with parathyroid hormone (Forteo). Taking these medicines together does not build more bone density.8, 9 But taking the two medicines at different times and in a specific order may build more bone density. For example, you could take parathyroid hormone for one year and then take a bisphosphonate for the following year to maintain or build bone density.10
Side Effects
Side effects are uncommon if the medicine is taken as directed, but may include:
- Heartburn, abdominal pain, and irritation of the esophagus.
- Headache and pain in muscles and joints.
- Constipation, diarrhea, and increased gas (flatulence).
- Difficulty swallowing (dysphagia).
- Allergic reactions.
Serious problems with bone healing, particularly after dental surgery, have been found in some people taking bisphosphonates.11 If you are taking bisphosphonates and need dental surgery, talk with your doctor.
Taking zoledronic acid may be linked to having an irregular heartbeat called atrial fibrillation.
See Drug Reference for a full list of side effects. (Drug Reference is not available in all systems.)
What To Think About
The long-term effects of taking bisphosphonates for many years are not known.
For the best results
and to reduce the risk of irritation to your
esophagus
if you take bisphosphonates by mouth:
- Take bisphosphonates in the morning with a full glass of water at least 30 minutes before eating a meal, drinking a beverage, or taking any other medicine.
- Sit or stand (don't lie down) for at least 30 minutes after taking a bisphosphonate. This helps prevent heartburn.
- Do not take a bisphosphonate late in the day if you forgot to take it in the morning.
If you are taking bisphosphonates, you should also take calcium and vitamin D supplements. But calcium supplements may interfere with your body's ability to absorb bisphosphonates, so they should not be taken at the same time of day.
Complete the
new medication information form (PDF)
(What is a PDF document?)
to help you understand this medication.
References
Citations
Alendronate (Fosamax) and risedronate (Actonel) revisited (2005). Medical Letter on Drugs and Therapeutics. 47(1207): 33–34.
Bone JG, et al. (2004). Ten years' experience with alendronate for osteoporosis in postmenopausal women. New England Journal of Medicine, 350(12): 1189–1199.
Harris ST, et al. (2001). Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 86(5): 1890–1897.
Greenspan SL, et al. (2003). Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women. JAMA, 289(19): 2525–2533.
National Heart, Lung, and Blood Institute (2003). Postmenopausal hormone therapy: Questions and answers. Available online: http://www.nhlbi.nih.gov/health/women/q_a.htm.
Orwoll E, et al. (2000). Alendronate for the treatment of osteoporosis in men. New England Journal of Medicine, 343(9): 604–610.
Black DM, et al. (2007). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New England Journal of Medicine, 356(18): 1809–1822.
Black DM, et al. (2003). The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New England Journal of Medicine, 349(13): 1207–1215.
Finklestein JS, et al. (2003). The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. New England Journal of Medicine, 349(13): 1216–1226.
Black DM, et al. (2005). One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. New England Journal of Medicine, 353(6): 555–565.
Woo S-B, et al. (2006). Systematic review: Bisphosphonates and osteonecrosis of the jaw. Annals of Internal Medicine, 144(10): 753–761.
Last Updated:
December 1, 2006- Author:
- Robin Parks, MS
- Medical Review:
- Joy Melnikow, MD, MPH - Family Medicine
Carla J. Herman, MD, MPH - Internal Medicine
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.




